McKesson Lifts FY27 EPS Outlook to $45.60–$46.40 After Q2 Beat
MCK sits 45% above its 52-week low of $723.68.
Summary
McKesson posted fiscal Q2 revenue of $110.96 billion, up 8% year over year, and adjusted EPS of $11.68, beating estimates. It now guides fiscal 2027 adjusted EPS to $45.60–$46.40, above the $44.20–$45.00 range it gave in September. The company also closed its Precision Medicine Group acquisition on November 2, 2026, and will buy about 49% of Option Care Health for $1.4 billion, subject to closing conditions. The CVS Health distribution deal now runs through June 2032. Segment growth was led by Oncology & Multispecialty at 24%, with Prescription Technology Solutions at 10% and Medical-Surgical Solutions at 5%. The planned separation of the medical-surgical segment into an independent company remains on track.
At the time of this announcement, MCK was trading at $1,049.50 on NYSE in the Trade & Services sector, with a market capitalization of approximately $124.7B. The 52-week trading range was $723.68 to $1,073.95. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.